Verici Dx plans equity fundraising to support Tutivia test growth

Verici Dx (VRCI) announced plans for an equity fundraising, including a placing and retail offer, to bolster its cash reserves and support the commercial expansion of its Tutivia diagnostic test. The company anticipates achieving $3.2 million in Tutivia revenue for FY25, aligning with market forecasts, and its cash runway is extended to at least the end of July 2025 due to a $750,000 milestone payment from Thermo Fisher and anticipated Medicare receivables; the fundraising will utilize existing allotment authorities, negating the need for additional shareholder approval.

Analysis

Verici Dx plc (AIM:VRCI) is initiating an equity fundraising to extend its cash runway beyond the end of July 2025 and accelerate the commercial growth of its Tutivia diagnostic test. The company reports positive indications of support from both existing and new investors for this fundraising, which will comprise a placing and a retail offer, utilizing existing allotment authorities from its May 27, 2025 General Meeting, thus not requiring new shareholder approval for non-pre-emptive share issuance. Verici Dx maintains its fiscal year 2025 revenue guidance for Tutivia at $3.2 million, consistent with market expectations, a target supported by the recently secured Medicare Coverage for the test in April 2025. As of May 31, Verici Dx's cash position was $1.04 million, bolstered by a $750,000 milestone payment from Thermo Fisher (NYSE:TMO) related to its Pre Transplant Risk Assessment test and anticipated Medicare receivables. The company plans to release its audited results for the year ended December 31, 2024, and further details on the fundraising before the end of June. This capital raise, viewed with moderately positive sentiment for VRCI, is crucial for navigating the commercialization phase, particularly given its current cash reserves.

Key Decisions for Investors

• Investors should carefully evaluate the terms of the forthcoming equity fundraising, including the quantum and pricing, to understand the potential dilutive impact on their holdings and the adequacy of the capital raised for achieving commercial milestones.
• Consider the company's progress in commercializing Tutivia, its ability to meet the $3.2 million FY25 revenue target, and the financial runway provided by this raise against the backdrop of ongoing cash requirements inherent in the biotech sector.
• Monitor upcoming announcements, specifically the audited FY2024 results and the specific details of the fundraising expected by the end of June, as these will provide critical data points for assessing Verici Dx's financial health and growth trajectory.